Sign in

George Gaspar

Research Analyst at Private Investor

George Gaspar is a Research Analyst at Private Investor, focusing on equities analysis with a track record of in-depth company-specific inquiry. He has covered individual companies such as Blonder Tongue Laboratories, where he has participated in earnings calls and conducted targeted research. While comprehensive long-term performance metrics and ranking details are not publicly available, his professional contributions are evident through active engagement in company analysis. Information about his career history, prior experience, and regulatory credentials is currently limited in the public domain.

George Gaspar's questions to BLONDER TONGUE LABORATORIES (BDRL) leadership

Question · Q3 2022

Private investor George Gaspar inquired about the sales contribution from products introduced in the last 12 months and questioned why the company hasn't pursued a broader financing program. He also asked if the company is nearing a positive inflection point for margins due to stabilizing costs and price increases, and requested a breakdown of the sales backlog by new versus older products.

Answer

CEO Ted Grauch highlighted significant growth in newer, higher-margin product lines like NXG (up 52% YoY) and encoders (up 9.1% YoY) but did not provide a precise sales percentage for all new products. CFO Eric Skolnik explained that financing opportunities are limited for a company of their size but noted they successfully extended their credit facility. CEO Ted Grauch added that while raw material costs have stabilized, not decreased, the company has raised prices and is nearly caught up on lower-priced backlog orders, which should improve margins going forward. He could not provide a specific breakdown of the backlog but confirmed a healthy portion is from new product lines.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts